ENDPOINTS

Edgewise details pivotal plans in Becker muscular dystrophy; Kymera’s $250M offering

Plus, news about Hummingbird, Percheron, Pfizer and I-Mab: Edgewise Therapeutics can’t get accelerated approval for muscle disease drug: The biotech said the FDA deemed its Phase 2 CANYON data "insufficient for ...

Jun 26, 2025 - 16:12
 0
Edgewise details pivotal plans in Becker muscular dystrophy; Kymera’s $250M offering
Plus, news about Hummingbird, Percheron, Pfizer and I-Mab: Edgewise Therapeutics can’t get accelerated approval for muscle disease drug: The biotech said the FDA deemed its Phase 2 CANYON data "insufficient for ...
Read More

Tags:

Previous Article

Alien life could survive deadly stellar radiation, Earth's desert lichen reveal

Next Article

Addendum: Unravelling cysteine-deficiency-associated rapid weight loss

Related Posts

Politics collide with science ahead of new ACIP meeting

Politics collide with science ahead of new ACIP meeting

Jun 23, 2025  0

White House threatens ‘most favored nation’ plan to lower US commercial drug prices

White House threatens ‘most favored nation’ plan to low...

May 12, 2025  0

#ASCO25: Immatics reports more early-stage data for melanoma cell therapy with pivotal trial underway

#ASCO25: Immatics reports more early-stage data for mel...

May 31, 2025  0